Live·Verified funding discovery · 2026.2
874 grants · 19 open · 435 companies · 2640 concepts874 / 19 / 435 / 2640
△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA
← Back to Eternal Search
Sapan A. Shah

Sapan A. Shah

individual
Ecosystem influencer

About

Sapan A. Shah, Ph.D., is a biotechnology executive serving as CEO of Glyscend Therapeutics, a venture-backed clinical-stage company developing gut-targeted therapies for type 2 diabetes and obesity. Glyscend's 2023 appointment announcement says he previously served as CEO of StrideBio, ARMGO Pharma, Ezose Sciences, and Shionogi Inc., and earlier worked as a consultant at McKinsey & Company. A 2009 Shionogi annual report identifies him as CEO of Shionogi USA, reflecting a long operating career in biopharma company building, development, and commercialization.

Areas of interest

biotechmetabolic diseaseobesitytype 2 diabetesgene therapyrare disease therapeuticsdrug developmentbiopharma company building